title: Thiomorpholine Derivatives with Hypolipidemic and Antioxidant Activity.
abstract: A number of thiomorpholine derivatives that are structurally similar to some substituted morpholines possessing antioxidant and hypocholesterolemic activity were synthesized. The new compounds incorporate an antioxidant moiety as the thiomorpholine N-substituent. The derivatives were found to inhibit the ferrous/ascorbate-induced lipid peroxidation of microsomal membrane lipids, with IC50 values as low as 7.5 µΜ. In addition, these compounds demonstrate hypocholesterolemic and hypolipidemic action. The most active compound (5) decreases the triglyceride, total cholesterol, and low-density lipoprotein levels in the plasma of Triton WR-1339-induced hyperlipidemic rats, by 80, 78, and 76%, respectively, at 56 mmol/kg (i.p.). They may also act as squalene synthase inhibitors. The above results indicate that the new molecules may be useful as leads for the design of novel compounds as potentially antiatherogenic factors.
authors.affiliation: Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Kyriaki-Konstantina
authors.initials: KK
authors.lastname: Tooulia
authors.affiliation: Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Theodosis-Nobelos
authors.affiliation: Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki, Greece.
authors.forename: Eleni A
authors.initials: EA
authors.lastname: Rekka
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D000975:Antioxidants / Q000138:chemical synthesis* / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D015227:Lipid Peroxidation / Q000187:drug effects; D008077:Lipoproteins, LDL / Q000097:blood; D015394:Molecular Structure; D009025:Morpholines / Q000138:chemical synthesis* / Q000494:pharmacology*; D011092:Polyethylene Glycols; D051381:Rats; D013329:Structure-Activity Relationship; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D000975:Antioxidants; D015415:Biomarkers; D004791:Enzyme Inhibitors; D008077:Lipoproteins, LDL; D009025:Morpholines; D014280:Triglycerides; C028971:thiamorpholine; D011092:Polyethylene Glycols; D002784:Cholesterol; D013186:Farnesyl-Diphosphate Farnesyltransferase; C016811:tyloxapol
keywords: Antioxidants; Cholesterol; Thiomorpholines; Triglycerides